CRISPRed Macrophages for Cell-Based Cancer Immunotherapy

Overview

Journal Bioconjug Chem

Publisher American Chemical Society

Specialty Biochemistry

Date 2018 Jan 4

PMID 29298051

Citations 50

Authors

Moumita Ray

Yi-Wei Lee

Joseph Hardie

Rubul Mout

Gulen Yesilbag Tonga

Michelle E Farkas

Vincent M Rotello

Affiliations

Soon will be listed here.

Abstract

We present here an integrated nanotechnology/biology strategy for cancer immunotherapy that uses arginine nanoparticles (ArgNPs) to deliver CRISPR-Cas9 gene editing machinery into cells to generate SIRP-α knockout macrophages. The NP system efficiently codelivers single guide RNA (sgRNA) and Cas9 protein required for editing to knock out the "don't eat me signal" in macrophages that prevents phagocytosis of cancer cells. Turning off this signal increased the innate phagocytic capabilities of the macrophages by 4-fold. This improved attack and elimination of cancer cells makes this strategy promising for the creation of "weaponized" macrophages for cancer immunotherapy.

Citing Articles

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?.

Bhatia D, Dolcetti R, Mazzieri R J Exp Clin Cancer Res. 2025; 44(1):98.

PMID: 40089746 DOI: 10.1186/s13046-025-03359-x.

Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.

Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang H Front Immunol. 2025; 16:1544532.

PMID: 40046061 PMC: 11880241. DOI: 10.3389/fimmu.2025.1544532.

Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine.

Azeez S, Hamad R, Hamad B, Shekha M, Bergsten P Front Genome Ed. 2024; 6:1509924.

PMID: 39726634 PMC: 11669675. DOI: 10.3389/fgeed.2024.1509924.

Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.

Li R, Huang J, Wei Y, Wang Y, Lu C, Liu J Int J Nanomedicine. 2024; 19:13615-13651.

PMID: 39717515 PMC: 11665441. DOI: 10.2147/IJN.S491573.

Uricase-Expressing Engineered Macrophages Alleviate Murine Hyperuricemia.

Feng Y, Cheng H, Xiong G, Cui J, Chen Z, Lu Y Biomedicines. 2024; 12(11).

PMID: 39595167 PMC: 11592275. DOI: 10.3390/biomedicines12112602.

References

Chao M, Weissman I, Majeti R . The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012; 24(2):225-32. PMC: 3319521. DOI: 10.1016/j.coi.2012.01.010. View

Chao M, Tang C, Pachynski R, Chin R, Majeti R, Weissman I . Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011; 118(18):4890-901. PMC: 3208297. DOI: 10.1182/blood-2011-02-338020. View

Ran F, Hsu P, Wright J, Agarwala V, Scott D, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11):2281-2308. PMC: 3969860. DOI: 10.1038/nprot.2013.143. View

Willingham S, Volkmer J, Gentles A, Sahoo D, Dalerba P, Mitra S . The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012; 109(17):6662-7. PMC: 3340046. DOI: 10.1073/pnas.1121623109. View

Ray M, Tang R, Jiang Z, Rotello V . Quantitative tracking of protein trafficking to the nucleus using cytosolic protein delivery by nanoparticle-stabilized nanocapsules. Bioconjug Chem. 2015; 26(6):1004-7. PMC: 4743495. DOI: 10.1021/acs.bioconjchem.5b00141. View

Tang R, Kim C, Solfiell D, Rana S, Mout R, Velazquez-Delgado E . Direct delivery of functional proteins and enzymes to the cytosol using nanoparticle-stabilized nanocapsules. ACS Nano. 2013; 7(8):6667-6673. PMC: 3757120. DOI: 10.1021/nn402753y. View

Chao M, Alizadeh A, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F . Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 2010; 71(4):1374-84. PMC: 3041855. DOI: 10.1158/0008-5472.CAN-10-2238. View

Weiskopf K, Ring A, Ho C, Volkmer J, Levin A, Volkmer A . Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013; 341(6141):88-91. PMC: 3810306. DOI: 10.1126/science.1238856. View

Chen J, Zhong M, Guo H, Davidson D, Mishel S, Lu Y . SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017; 544(7651):493-497. PMC: 5565268. DOI: 10.1038/nature22076. View

10.

Inagaki K, Yamao T, Noguchi T, Matozaki T, Fukunaga K, Takada T . SHPS-1 regulates integrin-mediated cytoskeletal reorganization and cell motility. EMBO J. 2000; 19(24):6721-31. PMC: 305898. DOI: 10.1093/emboj/19.24.6721. View

11.

Mitchem J, Brennan D, Knolhoff B, Belt B, Zhu Y, Sanford D . Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2012; 73(3):1128-41. PMC: 3563931. DOI: 10.1158/0008-5472.CAN-12-2731. View

12.

Chao M, Alizadeh A, Tang C, Myklebust J, Varghese B, Gill S . Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010; 142(5):699-713. PMC: 2943345. DOI: 10.1016/j.cell.2010.07.044. View

13.

Zhao X, van Beek E, Schornagel K, van der Maaden H, Van Houdt M, Otten M . CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A. 2011; 108(45):18342-7. PMC: 3215076. DOI: 10.1073/pnas.1106550108. View

14.

Panni R, Linehan D, DeNardo D . Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy. 2013; 5(10):1075-87. PMC: 3867255. DOI: 10.2217/imt.13.102. View

15.

Slee J, Christian A, Levy R, Stachelek S . Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors. Polymers (Basel). 2015; 6(10):2526-2551. PMC: 4333742. DOI: 10.3390/polym6102526. View

16.

Rossig C, Brenner M . Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004; 10(1):5-18. DOI: 10.1016/j.ymthe.2004.04.014. View

17.

Mout R, Ray M, Tonga G, Lee Y, Tay T, Sasaki K . Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. ACS Nano. 2017; 11(3):2452-2458. PMC: 5848212. DOI: 10.1021/acsnano.6b07600. View

18.

Ho C, Guo N, Sockolosky J, Ring A, Weiskopf K, Ozkan E . "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem. 2015; 290(20):12650-63. PMC: 4432284. DOI: 10.1074/jbc.M115.648220. View

19.

Zhang F . CRISPR-Cas9: Prospects and Challenges. Hum Gene Ther. 2015; 26(7):409-10. PMC: 4939442. DOI: 10.1089/hum.2015.29002.fzh. View

20.

Mout R, Ray M, Lee Y, Scaletti F, Rotello V . In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges. Bioconjug Chem. 2017; 28(4):880-884. PMC: 5846329. DOI: 10.1021/acs.bioconjchem.7b00057. View